Genmab — April 2019
-
"And you can see here in terms of what are recommendation premedications,..., the use of montelukast ...has changed the spectrum and the severity of infusion reactions.
It actually shortens the duration of that first infusion by about 2 hours on average, and it reduces the severity of the infusion reaction by one full grade. " -
Ny Janssen bispecific: https://clinicaltrials.gov/ct2/show/NCT03915379?term=JNJ-67571244&rank=1
-
"Two drugs stood out in boosting J&J’s results with better-than-expected sales. Anti-inflammatory treatment Stelara revenue increased to $1.41 billion from $1.06 billion, surpassing estimates of $1.36 billion. Multiple myeloma drug Darzalex increased to $629 million from $432 in the same time last year. Analysts had expected $627.7 million." cnbc https://www.cnbc.com/2019/04/16/johnson-johnson-q1-2019-earnings.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind